New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - dalteparin sodium 10000 iu/ml - solution for injection - 10000 iu/ml - active: dalteparin sodium 10000 iu/ml excipient: sodium chloride water for injection - · for the prevention of clotting in the extracorporeal system during haemodialysis and haemofiltration in connection with acute renal failure or chronic renal insufficiency

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - dalteparin sodium 12500 iu/ml - solution for injection - 12500 iu/ml - active: dalteparin sodium 12500 iu/ml excipient: water for injection - · for the prevention of clotting in the extracorporeal system during haemodialysis and haemofiltration in connection with acute renal failure or chronic renal insufficiency

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - dalteparin sodium 25000 iu/ml - solution for injection - 25000 iu/ml - active: dalteparin sodium 25000 iu/ml excipient: water for injection - · for the prevention of clotting in the extracorporeal system during haemodialysis and haemofiltration in connection with acute renal failure or chronic renal insufficiency

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - neisseria meningitidis group c polysaccharide 10ug (polysaccharide antigen from strain c11, conjugated to tetanus toxoid) - suspension for injection - 10 mcg/0.5ml - active: neisseria meningitidis group c polysaccharide 10ug (polysaccharide antigen from strain c11, conjugated to tetanus toxoid) excipient: aluminium hydroxide sodium chloride tetanus toxoid water for injection - active immunisation of children from 8 weeks of age, adolescents and adults for the prevention of invasive disease caused by neisseria meningitidis serogroup c.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - parecoxib sodium 21.18mg equivalent to 20 mg parecoxib;   - powder for injection - 20 mg - active: parecoxib sodium 21.18mg equivalent to 20 mg parecoxib   excipient: dibasic sodium phosphate heptahydrate nitrogen phosphoric acid sodium hydroxide hydrochloric acid nitrogen sodium chloride sodium hydroxide water for injection - for a single peri-operative dose for the management of post-operative pain.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - parecoxib sodium 42.36mg equivalent to 40 mg parecoxib;   - powder for injection - 40 mg - active: parecoxib sodium 42.36mg equivalent to 40 mg parecoxib   excipient: dibasic sodium phosphate heptahydrate nitrogen phosphoric acid sodium hydroxide hydrochloric acid nitrogen sodium chloride sodium hydroxide water for injection - for a single peri-operative dose for the management of post-operative pain.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - linezolid 600mg;  ; linezolid 600mg - film coated tablet - 600 mg - active: linezolid 600mg   excipient: carnauba wax hyprolose magnesium stearate maize starch opacode red s-1-5066 opadry white ys-1-18202 powdered cellulose sodium starch glycolate active: linezolid 600mg excipient: carnauba wax hyprolose magnesium stearate maize starch opacode red s-1-15118 opadry white ys-1-18202 powdered cellulose sodium starch glycolate - zyvox is indicated for the treatment of infections when known or suspected to be caused by susceptible organisms including those associated with concurrent bacteraemia such as: · pneumonia - community acquired and nosocomial pneumonia · skin and soft tissue infections · enterococcal infections. linezolid is active against gram-positive bacteria only. linezolid has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram-negative pathogen is documented or suspected. consideration should be given to official guidance on the appropriate use of antibacterial agents.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - linezolid 20 mg/ml - granules for oral suspension - 20 mg/ml - active: linezolid 20 mg/ml excipient: ammonium glycyrrhizinate aspartame citric acid monohydrate colloidal silicon dioxide dispersible cellulose sweet-am powder #918.005 nor-cap natural & artificial orange cream mannitol orange flavour (cream) 884.010 orange flavour 884.114 peppermint flavour sd f93125 sodium benzoate sodium chloride sodium citrate dihydrate sucrose sweet flavour (am) 918.005 vanilla flavour 712729 (mc008927) xanthan gum - zyvox is indicated for the treatment of infections when known or suspected to be caused by susceptible organisms including those associated with concurrent bacteraemia such as: · pneumonia - community acquired and nosocomial pneumonia · skin and soft tissue infections · enterococcal infections. linezolid is active against gram-positive bacteria only. linezolid has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram-negative pathogen is documented or suspected. consideration should be given to official guidance on the appropriate use of antibacterial agents.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - linezolid 2 mg/ml - solution for infusion - 2 mg/ml - active: linezolid 2 mg/ml excipient: citric acid glucose monohydrate hydrochloric acid sodium citrate dihydrate sodium hydroxide - zyvox is indicated for the treatment of infections when known or suspected to be caused by susceptible organisms including those associated with concurrent bacteraemia such as: · pneumonia - community acquired and nosocomial pneumonia · skin and soft tissue infections · enterococcal infections. linezolid is active against gram-positive bacteria only. linezolid has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram-negative pathogen is documented or suspected. consideration should be given to official guidance on the appropriate use of antibacterial agents.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - varenicline tartrate 0.85mg equivalent to 0.5 mg varenicline;  ;   - film coated tablet - 0.5 mg - active: varenicline tartrate 0.85mg equivalent to 0.5 mg varenicline     excipient: calcium hydrogen phosphate colloidal silicon dioxide croscarmellose sodium magnesium stearate microcrystalline cellulose opadry clear ys-2-19114-a opadry white ys-1-18202 - an aid to smoking cessation